Literature DB >> 9569631

In vitro susceptibility of 90 penicillin-susceptible and -resistant pneumococci to penicillin G, amoxicillin, amoxicillin/clavulanate, cefaclor, cefuroxime, cefpodoxime, cefixime and imipenem.

H Hupková1, J Trupl.   

Abstract

In vitro susceptibility of eight antibiotics was compared using three groups of pneumococci and agar dilution method comprising 30 penicillin-susceptible, 30 intermediately penicillin-resistant, and 30 highly penicillin-resistant pneumococci. Decreased sensitivity to all beta-lactam agents of intermediately penicillin-resistant and highly penicillin-resistant pneumococci is shown. MIC50 and MIC90 was lower with amoxicillin with and without clavulanate by one dilution than with penicillin. Cephalosporin MIC90s were all significantly higher for intermediately resistant and fully resistant strains. Only imipenem was more active than penicillin with MIC90 of susceptible pneumococci 0.015 mg/L, intermediately resistant pneumococci 0.25 mg/L, resistant pneumococci 1 mg/L.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9569631     DOI: 10.1007/BF02815546

Source DB:  PubMed          Journal:  Folia Microbiol (Praha)        ISSN: 0015-5632            Impact factor:   2.099


  10 in total

1.  Decreased susceptibility of penicillin-resistant pneumococci to twenty-four beta-lactam antibiotics.

Authors:  J Liñares; T Alonso; J L Pérez; J Ayats; M A Domínguez; R Pallarés; R Martín
Journal:  J Antimicrob Chemother       Date:  1992-09       Impact factor: 5.790

2.  Penicillin-binding protein families: evidence for the clonal nature of penicillin resistance in clinical isolates of pneumococci.

Authors:  D Jabes; S Nachman; A Tomasz
Journal:  J Infect Dis       Date:  1989-01       Impact factor: 5.226

3.  The incidence of penicillin-resistant pneumococci in the Slovak Republic. Pneumococcus Study Group.

Authors:  J Trupl; H Hupková; P C Appelbaum; M R Jacobs
Journal:  Chemotherapy       Date:  1997 Sep-Oct       Impact factor: 2.544

4.  In vitro susceptibility of pneumococci to trovafloxacin, penicillin G, and other antimicrobial agents in the Czech Republic and Slovakia.

Authors:  P Urbásková; J Trupl; H Hupková; P C Appelbaum; M R Jacobs
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-08       Impact factor: 3.267

Review 5.  Multiply-resistant pneumococcus: therapeutic problems in the management of serious infections.

Authors:  P D Lister
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995       Impact factor: 3.267

Review 6.  Genetics and molecular biology of beta-lactam-resistant pneumococci.

Authors:  T J Coffey; C G Dowson; M Daniels; B G Spratt
Journal:  Microb Drug Resist       Date:  1995       Impact factor: 3.431

Review 7.  Antimicrobial resistance in Streptococcus pneumoniae: an overview.

Authors:  P C Appelbaum
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

8.  Trends in antibiotic resistance of respiratory pathogens: an analysis and commentary on a collaborative surveillance study.

Authors:  F Baquero
Journal:  J Antimicrob Chemother       Date:  1996-07       Impact factor: 5.790

9.  Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillin-susceptible and -resistant pneumococci.

Authors:  S K Spangler; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

Review 10.  Neurotoxicity of beta-lactam antibiotics: predisposing factors and pathogenesis.

Authors:  S E Schliamser; O Cars; S R Norrby
Journal:  J Antimicrob Chemother       Date:  1991-04       Impact factor: 5.790

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.